- Lobbying
- thornhill AND research
Lobbying Arrangements Results for 'Thornhill Research'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details FY 2007 Defense Authorization and Appropriation Bills DOD Research and Development |
Thornhill Research, Inc.
Medical technology product development |
Capitol Resources Washington Representation LLC | |||
Details FY11 National Defense Authorization Act; FY11 Department of Defense Appropriations in the following issue areas: RDTE (Navy) and Procurment (Marine Corps) |
TriVirix
|
RM2 Consultants, Inc. | |||
Details Issues related to biopharma research and development. |
TechImmune LLC
|
Forbes-Tate | |||
Details S.___ Affordable Healthy Futures Act; America's Affordable Health Choices Act H.R.3200; Follow-on Biologics - H.R. 1427, H.R. 1548 |
Genentech, Inc.
|
FOLEY HOAG LLP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Johnson & Johnson
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details S 1390 - FY10 National Defense Authorization Act; HR 2647 - FY10 National Defense Authorization Act; HR 3326 - FY10 Department of Defense Appropriations in the following issue area: RDTE (Navy / Ma... |
SVTronics, Inc.
|
RM2 Consultants, Inc. (formerly Capitol Resources Washington Representation LLC) | |||
Details Congressional deficit reduction negotiations and Deficit Reduction Commission, following passage of the Budget Control Act of 2011 (P.L. 112-25) |
ASTRAZENECA PHARMACEUTICALS LP
|
FOLEY HOAG LLP | |||
Details Patient Protection and Affordable Care Act (H.R. 3590); Health Care and Education Affordability Reconciliation Act (H.R. 4872) |
Bristol-Myers Squibb
|
FOLEY HOAG LLP | |||
Details Patent Reform - S 1145, HR 1908 FDA Globalization Act - HR 3610, S 3409 Follow-on Biologics -- S 1695, HR 1038, HR 1956 Physician Payments Sunshine Act: S 2029 |
BIOGEN IDEC, INC.
|
FOLEY HOAG LLP | |||
Details American Recovery and Reinvestment Act Compartive Effectiveness Research programs and regulations S 1213 - The Patient-Centered Outcomes Research Act of 2009 HR 2502 - The Comparative Effectiveness... |
Partnership to Improve Patient Care
|
FOLEY HOAG LLP | |||
Details General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure develop... |
Achaogen
|
THE MCMANUS GROUP | |||
Details Senate and House comprehensive health reform bills; S.__ Affordable Health Choices Act Comparative effectiveness research; patent reform Follow-on biologics legislation - H.R. 1427, H.R. 1548 Physi... |
BIOTECHNOLOGY INDUSTRY ORGANIZATION
|
FOLEY HOAG LLP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Spero Opco, Inc.
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Astellas Pharma US, Inc.
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
The Medicines Company
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Tetraphase Pharmaceuticals
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Microbion Corporation
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
AstraZeneca
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
GlaxoSmithKline
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Patient Protection and Affordable Care Act (P.L. 111-148) Health Care and Education Reconciliation Act (P.L. 111-152) Preserve Access to Affordable Generics Act- S. 369 Patent Reform- S. 515 Medica... |
MERCK
|
FOLEY HOAG LLP | |||
Details Issues related to the NASH Care Act - preventing, diagnosing, and treating nonalcoholic steatohepatitis. |
NASH Alliance Coalition
|
Forbes-Tate | |||
Details Issues related to monoclonal antibody discovery, research and development. |
Genovac, LLC
|
Forbes-Tate | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Zavante Therapeutics, Inc.
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act. |
Merck & Co., Inc.
Client manufacturers and develops pharmaceuticals, vaccines and biologic therapies. |
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Issues related to the federal governments response to COVID-19; Issues related to advanced research and development for COVID-19 response. Issues related to H.R. 925 - The Heroes Act. |
EUSA Pharma LLC
|
Forbes-Tate | |||
Details FY13 and FY14 DoD Budget Authorization and Appropriations to include CR and Sequestration Implications for Industry; Procurement and Fielding of the USMC's MOVES/PDLLS life support system. |
THORNHILL RESEARCH, INC.
|
RM2 Consultants, Inc. | |||
Details Issues related to market access and COVID-19. |
Kahala Biosciences
|
Forbes-Tate | |||
Details Issues related to the advancement of research and development. |
Syndax Pharmaceuticals
|
Forbes-Tate | |||
Details S.___ Affordable Healthy Futures Act; Americas Affordable Health Choices Act H.R.3200. The Patient-Centered Outcomes Research Act, S.1213; Comparative effectiveness research H.R.2505; Implementatio... |
GlaxoSmithKline
pharmaceutical company |
FOLEY HOAG LLP | |||
Details Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis. Policies regarding research, education, and prevention activities relating to nonalcoholic steat... |
NASH Alliance LLC
|
THE MCMANUS GROUP | |||
Details Patent Reform Legislation - S 515, HR 1260 FDA Globalization Act - HR 759 Follow-on biologics - HR1427, HR 1548 Physician Payments Sunshine Act - S 301 ARRA; CER Medicare Improvements for Patients ... |
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
|
FOLEY HOAG LLP | |||
Details Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis. Policies regarding research, education, and prevention activities relating to nonalcoholic steat... |
NASH Alliance
|
in-house lobbying | |||
Details Issues related to NIDA grants for the research and development of medical technology. Issues related to H.R. 925 - The Heroes Act. |
Abyrx, Inc.
|
Forbes-Tate | |||
Details Preserve Access to Affordable Generics Act - S.369 Patent Reform Act - S.515 Patient Protection and Affordable Care Act - H.R.3590 Affordable Health Care for America Act - HR 3962 Pathway for Bios... |
Eisai Corporation of North America
|
FOLEY HOAG LLP | |||
Details Issues related to infrastructure development. |
Modern Nitrile, LLC
|
Forbes-Tate | |||
Details Issues related to biopharmaceutical research and innovation. |
Revangenix
|
Forbes-Tate | |||
Details The re-authorization of the Pandemic and All-Hazards Preparedness Act. Funding for the Biomedical Advanced Research and Development Authority in the LHHS Appropriations bill. |
Pfenex, Inc.
|
East End Group, LLC | |||
Details Patent Reform S 515, HR 1260 Medicaid Rebate Issues FDA Globalization Act HR 759 Pharmaceutical coverage and reimbursement issues associated wtih American Recovery and Reinvestment Act of 2009 Foll... |
MedImmune, Inc.
|
FOLEY HOAG LLP | |||
Details Legislatives issues related to biodefense preparedness and response, and the reauthorization of the Pandemic and All-Hazards Preparedness Act. Funding for the Biomedical Advanced Research and Devel... |
Bavarian Nordic, Inc.
|
East End Group, LLC | |||
Details Issues related to medical education and research. |
Association of American Medical Colleges
|
Forbes-Tate | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act. |
Allergan, Plc.
Allergan is a diversified global pharmaceutical company |
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Medicare payment for inpatient antibiotics. |
Antimicrobial Innovation Alliance
|
THE MCMANUS GROUP | |||
Details Issues related to biopharmaceutical research, development and commercialization. |
Spero Therapeutics, Inc.
|
Forbes-Tate | |||
Details General health care coverage and reimbursement for prescription drugs; drug pricing reform and related issues; and the Food and Drug Administration legislative and regulatory issues. |
The Pharmaceutical Research and Manufacturers of America
|
East End Group, LLC | |||
Details Access and reimbursement of medical devices in Medicare program. Access and reimbursement of medical devices in Medicare program including in H.R.1691 - Ensuring Patient Access to Critical Breakth... |
Zimmer Biomet
|
THE MCMANUS GROUP | |||
Details Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.2880 - Protecting Patients Against PBM... |
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
|
THE MCMANUS GROUP | |||
Details -Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development ... |
Sanofi US Services, Inc.
|
FOLEY HOAG LLP | |||
Details Issues related to legislation to provide relief during the COVID-19 pandemic; Issues related to advanced research and development for COVID-19 response. Issues related to H.R. 925 - The Heroes Act. |
Bellerophon Therapeutics
|
Forbes-Tate | |||
Details Issues related to biomedical research and development; Issues related to pathogen surveillance. |
Bio-Rad Laboratories
|
Forbes-Tate | |||
Details Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC). Issues related to Medicare and Medicaid payments... |
American College of Radiology Association
|
Forbes-Tate |